Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01824992

Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections

a Multi-sites, Randomized, Parallel, Controlled Clinical Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection

Sponsor: Lee's Pharmaceutical Limited

Conditions HPV Infection

Interventions Yallaferon®

Updated 6 times since 2017 Last updated: Apr 4, 2013 Started: Mar 31, 2011 Primary completion: Mar 31, 2012 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01824992, this PHASE2/PHASE3 trial focuses on HPV Infection and remains completed. Sponsored by Lee's Pharmaceutical Limited, it has been updated 6 times since 2011, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lee's Pharmaceutical Limited

Data source: Lee's Pharmaceutical Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.